
|Videos|July 13, 2023
Efficacy of Subsequent Therapies in Advanced Ovarian Cancer
Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.

Trine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC
5
